ADGRE2 CAR-T (Zhejiang University)

N/A

Report date: 2025/01/08 17:06:52

Base Information

Drug NameADGRE2 CAR-T (Zhejiang University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAdhesion G protein-coupled receptor E2 modulators
TargetsAdhesion G protein-coupled receptor E2
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A